Spruce Biosciences, Inc. (SPRB)
After hours:
| Previous close | 1.3200 |
| Open | 1.4600 |
| Bid | 1.2500 x 3000 |
| Ask | 1.3000 x 800 |
| Day's range | 1.2500 - 1.4600 |
| 52-week range | 1.2500 - 15.0800 |
| Volume | |
| Avg. volume | 125,295 |
| Market cap | 30.306M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.8860 |
| Earnings date | 09 Aug 2022 - 15 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.17 |
- Business Wire
Spruce Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update
SAN FRANCISCO, May 11, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2022 and provided corporate updates.
- Business Wire
Spruce Biosciences to Participate in May Investor Conferences
SAN FRANCISCO, May 03, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming investor conferences taking place in May.
- Business Wire
Spruce Biosciences Appoints Libbie Mansell, Ph.D., M.B.A., R.A.C., as Chief Regulatory and Quality Officer
SAN FRANCISCO, April 11, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Libbie Mansell, Ph.D., M.B.A., R.A.C., has been appointed Chief Regulatory and Quality Officer. Dr. Mansell will be responsible for leading the company’s global regulatory affairs and quality strategy.
